Recommendation of mavacamten posology by model‐based analyses in adults with obstructive hypertrophic cardiomyopathy

• Hlavní autoři: Samira Merali (Autor), David H. Salinger (Autor), Maria Palmisano (Autor), Amy J. Sehnert (Autor), Neelima Thanneer (Autor), Hyunmoon Back (Autor), Julie D. Seroogy (Autor), Daniel D. Gretler (Autor), Amit Roy (Autor), Vidya Perera (Autor)
• Médium: Kniha
• Vydáno: Wiley, 2024-09-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

Abstract Mavacamten is the first cardiac myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The phase III EXPLORER‐HCM (NCT03470545) study used a dose‐titration scheme based on mavacamten exposu...